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Abstract Myosin binding protein-C (MyBP-C), a major
thick ﬁlament associated sarcomeric protein, plays an
important functional and structural role in regulating sar-
comere assembly and crossbridge formation. Missing or
aberrant MyBP-C proteins (both cardiac and skeletal) have
been shown to cause both cardiac and skeletal myopathies,
thereby emphasising its importance for the normal func-
tioning of the sarcomere. Mutations in cardiac MyBP-C are
a major cause of hypertrophic cardiomyopathy (HCM),
while mutations in skeletal MyBP-C have been implicated
in a disease of skeletal muscle—distal arthrogryposis type
1 (DA-1). Here we report the ﬁrst detailed electron
microscopy studies on human cardiac and skeletal tissues
carrying MyBP-C gene mutations, using samples obtained
from HCM and DA-1 patients. We have used established
image averaging methods to identify and study the axial
distribution of MyBP-C on the thick ﬁlament by averaging
proﬁle plots of the A-band of the sarcomere from electron
micrographs of human cardiac and skeletal myopathy
specimens. Due to the difﬁculty of obtaining normal human
tissue, we compared the distribution to the A-band struc-
ture in normal frog skeletal, rat cardiac muscle and in
cardiac muscle of MyBP-C-deﬁcient mice. Very similar
overall proﬁle averages were obtained from the C-zones in
cardiac HCM samples and skeletal DA-1 samples with
MyBP-C gene mutations, suggesting that mutations in
MyBP-C do not alter its mean axial distribution along the
thick ﬁlament.
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Abbreviations
MyBP-C Myosin binding protein-C
HCM Hypertrophic cardiomyopathy
DA-1 Distal arthrogryposis type 1
EM Electron microscopy
IgI Immunoglobulin
FnIII Fibronectin type III
LMM Light meromyosin portion of the myosin rod
cMyBP-C Human cardiac myosin binding protein-C
ssMyBP-C Human slow skeletal myosin binding
protein-C
wt Wild type
ko Knock out
Introduction
Myosin binding protein-C (MyBP-C) is a 140 kDa sarco-
meric protein that binds to the thick ﬁlament in vertebrate
striated muscle and can be visualised as 7–9 stripes of
separation 43 nm in the C-zone of the sarcomere. It was
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et al. (1973) as a contaminant in the preparation of puriﬁed
myosin. There are three isoforms, slow skeletal, fast skel-
etal and cardiac, encoded by the genes MYBPC1, MYBPC2
and MYBPC3 and located on chromosome 12, 19 and 11
respectively (for reviews see Flashman et al. 2004; Harris
et al. 2011; Schlossarek et al. 2011). All three isoforms
share a conserved domain architecture, composed of seven
immunoglobulin (IgI) domains and three ﬁbronectin type
III (FnIII) domains depicted as C1–C10 (Fig. 1a), with a
105 residue domain between C1 and C2 called the
M-domain or MyBP-C motif and a proline- and alanine-
rich region near the N-terminus (Gautel et al. 1995; Ok-
agaki et al. 1993). The cardiac isoform differs from the
skeletal isoform in three major ways: it has an additional Ig
domain, C0, at the N-terminus; it has 3 phosphorylation
sites in the M-domain and the domain C5 has a proline-rich
25 residue insertion (Gautel et al. 1995). The homology of
the amino acids in all three isoforms is high, with 39.6 %
sequence identity in the human isoforms.
There is evidence that suggests that MyBP-C interacts
with thick ﬁlaments, thin ﬁlaments and titin. It binds to
light meromyosin portion of the myosin rod (LMM) and
titin via its C-terminal domains C7–C10 (Freiburg and
Gautel 1996). In vitro experiments show that MyBP-C can
modulate actin–myosin interaction by binding to actin ﬁl-
aments (Moos et al. 1978; Kulikovskaya et al. 2003;
Shaffer et al. 2009). This has been visualised in a recent
thick ﬁlament reconstruction which showed clear MyBP-C
density perpendicular to the ﬁlament, extending beyond the
myosin heads, and making contact with actin ﬁlaments
(Luther et al. 2011). Furthermore, a weak interaction has
also been observed in vitro between MyBP-C and myosin
S2, and this interaction is mediated through domains C1–
C2 (Starr and Offer 1978; Gruen and Gautel 1999). A
schematic arrangement of the cardiac isoform of MyBP-C
with respect to the ﬁlament systems is shown in Fig. 1b.
The precise arrangement of the C-terminus of MyBP-C in
the sarcomere with respect to myosin remains unresolved,
since there is evidence that suggests both a trimeric collar
arrangement (Moolman-Smook et al. 2000) and an axial
arrangement (Squire et al. 2003; Zoghbi et al. 2008). The
interaction between MyBP-C, myosin, and titin is believed
to be responsible for maintaining the ordered arrangement
Fig. 1 Organisation of MyBP-
C. a Schematic showing the
domain architecture of cardiac
and skeletal MyBP-C. The
protein is composed of repeats
of IgI-like and FnIII-like
domains. PA-domain refers to
the proline–alanine rich linker
region while M-domain refers to
the 105 residue domain between
C1 and C2 also called MyBP-C
motif. b Schematic arrangement
of cardiac MyBP-C (cMyBP-C)
with respect to the components
of the sarcomere. Here the
C-terminal of cMyBP-C is
arranged parallel to the thick
ﬁlament backbone (Squire et al.
2003), while the N-terminal is
shown interacting with a thin
ﬁlament
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123of the sarcomere (Freiburg and Gautel 1996). Furthermore
phosphorylation of the cardiac isoform modulates con-
tractility and also regulates cross-bridge kinetics (Bareﬁeld
and Sadayappan 2010).
The importance of MyBP-C for the normal functioning
of the sarcomere is further emphasised by the occurrence of
cardiac and skeletal myopathies due to missing or aberrant
MyBP-C proteins. Mutations in MYBPC3 encoding cardiac
MyBP-C (cMyBP-C) are a major cause of hypertrophic
cardiomyopathy (HCM), a disease that is estimated to
affect 1 in 500. It is characterised by a thickening of the left
ventricular wall, signiﬁcant myoﬁbrillar disarray and
interstitial ﬁbrosis. Mutations in MYBPC1 encoding slow-
skeletal MyBP-C (ssMyBP-C) have recently been impli-
cated in a disease of skeletal muscle—distal arthrogryposis
type 1 (DA-1)—characterised by congenital contracture of
distal limbs. So far two DA-1 causing MYBPC1 mutations
have been identiﬁed, while 197 HCM causing MYBPC3
mutations have been reported (Alcalai et al. 2008; Gurnett
et al. 2010; for reviews see Harris et al. 2011 and Sch-
lossarek et al. 2011). Both diseases are transmitted as
autosomal-dominant traits, but studies by Gurnett et al.
(2010), indicate that the MYBPC1 and MYBPC3 mutations
may adopt different disease causing mechanisms.
Although research into MYBPC1 mutations is relatively
limited, the mutations in MYBPC3 (cardiac isoform) have
been more extensively researched for the last 15 years.
Remarkable headway has been made in understanding the
genetic mechanisms and functional consequence of the
MYBPC3 mutations in HCM. Work has been carried out by
Luther et al. (2008) using electron microscopy to visualise
healthy, small animal and cMyBP-C knockout mouse sar-
comeres (cardiac and skeletal). However the structural
consequence of these mutations to the thick ﬁlament and
sarcomere architecture in the diseased human tissues is
relatively unknown. Investigation into the ultrastructural
organisation of the sarcomere can help better understand
the functional shortcoming observed in these myopathies.
In this study electron microscopy and A-band analysis of
human cardiac and skeletal tissue from patients with MY-
BPC1 or MYBPC3 mutations has been carried out. Spe-
ciﬁcally we investigated the effect of the mutations on the
presence and axial distribution of MyBP-C into the C-zone
of the sarcomere.
Experimental procedures
Sample preparation
Skeletal
Muscle biopsy samples were conventionally processed and
embedded in Araldite epoxy resin. Semi-thick 0.5 lm
sections and thin 100 nm sections were cut with a Reichert
Ultracut E ultramicrotome. Thin sections picked on copper
grids were stained with 2 % uranyl acetate and Reynolds
lead citrate. The biopsy sample details are listed in Table 1.
In this manuscript, the two skeletal mutations will be
referred to as ss-W236R and ss-Y856H, respectively. The
frog skeletal samples were used as described in Luther
et al. (2008).
Cardiac
Myectomy samples were obtained either as freshly excised
tissue or snap frozen in liquid nitrogen. Freshly excised
cardiac tissue obtained directly after the myectomy pro-
cedure were incubated straightaway for 30 min in oxy-
genated Krebs solution (94.5 mM sodium chloride, 5 mM
potassium chloride, 25 mM sodium hydrogen carbonate,
1 mM disodium hydrogen phosphate, 1 mM magnesium
sulphate7H2O, 10 mM sodium acetate, 10 mM glucose
and 1 mM calcium chloride, pH 7.4) with 30 mM 2,3-
Table 1 Details of the myectomy and biopsy samples used in this study and the MyBP-C gene mutations identiﬁed
Isoform Mutation Sample code and detail Domain affected Diagnosis Reference
cMyBP-C c.1624G[C MH1 fresh tissue E542Q amino acid substitution
in the C3 domain or predicted
truncation at C3 domain due
to exon skipping
HCM Marston et al. (2011)
cMyBP-C InsG2374 M9 frozen sample, homogenised. Truncation at the C5 domain HCM Marston et al. (2009)
cMyBP-C c.472G[A M4 frozen sample, homogenised. V158M Polymorphism HCM Marston et al. (2009)
cMyBP-C None M24 fresh tissue, cryosections
prepared for em
Myectomy control HCM Marston et al. (2009)
ssMyBP-C c.706T[C ss-W236R fresh tissue W236R amino acid substitution
in the MyBP-C motif
DA-1 Gurnett et al. (2010)
ssMyBP-C c.2566T[C ss-Y856H fresh tissue Y856H amino acid substitution
in the C8 domain
DA-1 Gurnett et al. (2010)
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123butanedione monoxime (BDM) and then ﬁxed in 3 %
gultaraldehyde in Krebs solution for 1 h, followed by
secondary ﬁxation in 1 % osmium tetroxide for 30 min.
Dehydration using increasing concentrations of acetone
(50, 70, 80, 90, 95, 100 % and ﬁnally dry acetone) was then
carried out. The sample was subsequently embedded into
the epoxy resin Araldite CY 212. Alternatively, after ﬁx-
ation in 3 % glutaraldehyde, the tissue was prepared for
cryosectioning following the protocol described by Luther
et al. (2008).
Some of the myectomy samples were snap frozen in
liquid nitrogen. These samples were thawed and homog-
enised in cold relaxing solution (100 mM potassium
chloride, 20 mM imidazole, 2 mM magnesium chloride,
2m M K 2EGTA and 4 mM ATP) with 30 mM BDM
(10 ml) using a Polytron homogeniser and the resultant
suspension spun at 1,200 rpm for 1 min. The resulting
pellet was incubated in a skinning solution (relaxing
solution with 0.3 ml of 1 % Triton X) for 7 min (with
frequent rolling) before being spun again (1,200 rpm/
1 min). The sample was then spun twice more with fresh
relaxing solution (10 ml at room temperature) and to the
resultant sample cold relaxing solution (1 ml) was added
and left for 30 min over ice. The sample was then applied
onto Thermonox cover-slips with a Cytospin 3 and
chemically ﬁxed with 3 % glutaraldehyde in relaxing
solution for 15 min. Secondary ﬁxation, dehydration and
embedding steps were performed as described in the
preceding paragraph.
Semi-thick 0.5 lm and thin 100 nm sections from
araldite blocks were cut with a Reichert Ultracut E ultra-
microtome. Thin sections were picked on copper grids and
stained with 2 % uranyl acetate and Reynolds lead citrate.
Cryosections of frozen samples *100 nm thick were cut
with an RMC MT7 ultramicrotome ﬁtted with a CR20
cryoattachment, transferred to formvar/carbon-coated
nickel grids, and negative-stained with 2 % uranyl acetate.
The myectomy sample details are listed in Table 1. In this
manuscript, the cardiac mutation will be referred by their
sample codes as shown in Table 1. The preparation of rat
cardiac and cMyBP-ko mouse samples has been described
in detail in Luther et al. (2008).
Histology studies
The 0.5 lm semi-thick sections were stained with Paragon
stain (0.73 % toluidine blue, 0.27 % Basic Fuchsin in 30 %
ethanol) by combining the stain with saturated borax
solution in a 4:1 ratio on the slide. The slides were
examined using a Nikon inverted microscope using 209
objective and 1009 oil immersion objective and photo-
graphed with an Olympus E330 camera.
Electron microscopy
A JEOL 1200 EX electron microscope operated at 100 kV
was used to examine the grids. Images for the frog skeletal
muscle, rat cardiac muscle and three of the cardiac myec-
tomy tissues were recorded on electron microscope ﬁlm
(Kodak SO-163) at 20,0009 magniﬁcation and the ﬁlms
scanned with a Nikon Coolscan 8000ED 4,000 dpi scanner
and binned four times to give a pixel resolution of about
1.3 nm. Images for all the other samples were recorded
with a Tietz Fastscan CCD camera and Tietz EMMenu 4.0
software was used to view and record images at a range of
magniﬁcations (2,5009–15,0009).
Method for averaging proﬁle plots
The images were analysed as described by Luther et al.
(2008), using custom software written by C. Knupp and
ImageJ software. Brieﬂy, longitudinal regions were ﬁrst
rotated to make the cross bridge striations vertical, then
suitable half sarcomeres were boxed, band-pass ﬁltered and
the proﬁle plot data collected. The 1-D proﬁle plots
obtained were averaged by cross-correlation to produce an
average axial density plot.
Results
Human skeletal muscle was available from two patients
with slow skeletal MYBPC1 mutations obtained from
abductor hallucis muscle open biopsies (Gurnett et al.
2010). Both mutations occur in highly conserved regions.
The ﬁrst mutation, W236R, occurs in the MyBP-C motif,
while the second mutation, Y856H, occurs in the C8
domain.
Human cardiac samples used in this study were obtained
from inter-ventricular septum of HCM patients undergoing
surgical myectomy to relieve hypertrophic obstructive
cardiomyopathy. Four HCM myectomy samples were
analysed in this study (details in Table 1). Three of the
samples were identiﬁed with MYBPC3 mutations (MH1,
M9, and M4). MH1 was identiﬁed with G[C transversion
on the last nucleotide of exon 17 (c.1624G[C). This
mutation is predicted to produce either a mutant full length
protein with a missense E542Q mutation in the C3 domain
or lead to the skipping of exon 17 resulting in a premature
termination of the translation in the middle of C3 domain
of the molecule (Carrier et al. 1997). Direct measurements
showed substantial amounts of nonsense mRNA due to
skipping of exon 17 and there was a 28 % deﬁciency of
MyBP-C in this muscle (Marston et al. 2011). M9 was
identiﬁed as InsG2374, giving rise to polypeptide with a
premature termination at the C5 domain and is 90 kDa in
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123size. This peptide is not present in the muscle and hap-
loinsufﬁciency of 19 % was reported (Marston et al. 2009).
M4 contains a V158M mutation which was attributed to a
gene polymorphism that is unlikely to be disease causing
(Marston et al. 2009). No gene mutation was identiﬁed in
M24 and was therefore used as myectomy control in this
study. Details of all the samples used in this study are listed
in Table 1.
Histological analysis of the human samples
Histological examinations performed on 0.5 lm thick
plastic sections of the MyBP-C DA-1 patient samples are
shown in Fig. 2. The morphology of the samples was
highlighted by Paragon stain, which renders cellular com-
ponents dark blue and connective tissue such as collagen
pink. At lower magniﬁcation the staining of the muscle
ﬁbres is seen in blue, and at 1009, the striation pattern due
to the sarcomeres in the longitudinal orientation can be
clearly recognized in all the samples (both cardiac and
skeletal). Light micrographs recorded with 209 objective
and 1009 oil immersion objective are shown in Fig. 2. The
skeletal mutants displayed variable levels of staining for
connective tissue (Fig. 2a, b). The amount of connective
tissue appears to be more abundant in ss-Y856H (Fig. 2b)
compared to ss-W236R (Fig. 2a). The ss-W236R tissue
sections also show signs of severe bending of the myoﬁ-
brils in some regions (indicated by ‘‘*’’ symbol in Fig. 2a).
This is not an effect of sample mishandling because the
surrounding ﬁbres are normal (marked with a ? symbol).
This type of misalignment was not obvious for ss-Y856H
under the light microscope since most of the ﬁbres in the
sample were in the transverse orientation, but was more
clearly observed while imaging with EM (Ultrastructure of
the diseased tissue).
Histological examination of the cardiac samples MH1,
M4 and M9 are shown in Fig. 2c, d and e, respectively.
Staining for connective tissue is very clear for MH1
(Fig. 2c), but is less clear for M4 (Fig. 2d) and M9
(Fig. 2e) samples as they were prepared by homogenisation
and therefore most of the extra-sarcomeric features are lost.
Myoﬁbrillar disarray, a hallmark of the disease, is notice-
able for the MH1 sample; this was also evident from
hematoxylin and eosin staining of larger cryosections of
MH1 (data not shown).
Ultrastructure of the diseased tissue
The effects of the MyBP-C gene mutations on the general
features and ultrastructural organisation of the diseased
skeletal and cardiac muscle was studied by electron
microscopy at a range of low-medium magniﬁcations
(Figs. 3, 4). Longitudinal sections of the muscle were
examined for signs of myoﬁbrillar disarray and disorder
within sarcomeres. The electron micrographs of the skel-
etal mutations (ss-W236R and ss-Y856H) exhibited
regions with well-aligned and straight myoﬁbrils (Fig. 3a,
d), as well as, myoﬁbrils with a bent appearance (Fig. 3b,
e). However, the sarcomere itself is well preserved, and
features such as the Z-disc, M-band and I-bands are clearly
visible.
Electron micrographs for the cardiac samples MH1, M4
and M9 are shown in Fig. 4a, b, c, respectively. The
myoﬁbrillar organisation of these samples appears to be
well aligned. There is also no evidence of sarcomeric
disarray for all three samples. However the cardiac sarco-
meres appear to be contracted, and is especially evident for
MH1 and M9. There is also no obvious loss in structure and
features such as the Z-disc and M-band, but the I-band
region is less clear due to its contracted state (a and c).
Contracted sarcomeres are observed despite the addition of
30 mM BDM, a low-afﬁnity myosin inhibitor that selec-
tively inhibits actin-myosin interaction during the sample
preparation (Higuchi and Takemori 1989; Ostap 2002) and
prevents dissection-induced contracture (Mulieri et al.
1989). Therefore, this shortening of sarcomeres could be a
pathological manifestation of the disease causing mutation
(Pohlmann et al. 2007).
Average axial density distribution
One-dimensional analysis was carried out on human skel-
etal and cardiac muscle carrying MYBPC1 and MYBPC3
mutations respectively. Axial distribution of MyBP-C in
these samples was analysed by averaging proﬁle plots of
the A-band over several electron micrographs of half-sar-
comere regions by cross-correlation to produce an average
axial density proﬁle. The axial density plots for the skeletal
and cardiac samples are compared in Figs. 5 and 6,
respectively. The averaged half A-band plot was divided
into seventeen equally spaced bands of 43 nm intervals,
marked by red lines labelled 1–17 in Figs. 5 and 6,
although non-myosin protein is known to be present only
on stripes 1–11. Luther et al. (2008) have determined
previously by immuno-electron microscopy that the
C-zone in cardiac muscle is located between stripe 3 and
11, hence the P-zone (proximal) spans stripes 1–3. In these
ﬁgures, representative electron micrographs of the different
samples are shown in the left panel, while in the right panel
the plot proﬁles are arranged to line up at the centre of the
M-bands and the edges of the A-band marked by the two
green lines. The plots are regular and show peaks of high
density in the A-band region. As discussed below, the
majority of the peaks within the C-zone coincide with the
43 nm spaced red lines indicating the presence of one layer
of myosin crossbridges (crowns) and MyBP-C.
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123Fig. 2 Light microscopy
analysis of muscle biopsy and
cardiac myectomy samples
taken at 920 (LHS panels) and
9100 (RHS panels). Paragon
staining of semi thin sections of
a ss-W236R, b ss-Y856H,
c MH1, d M4 and e M9 is
shown; the stain highlights
cellular components in dark
blue and connective tissue pink.
Sarcomeric striations are
observed in all sections at
9100. Bar = 10 lm. (Color
ﬁgure online)
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123Fig. 3 Transmission electron micrographs of the skeletal biopsy
samples. Low and medium magniﬁcation overview of myoﬁbrillar
and sarcomeric ultrastructure of a–c ss-W236R and d–f ss-Y856H. a,
d show micrographs of regions with well-aligned and straight
myoﬁbrils; b, e EM of myoﬁbrils showing a ‘‘bent’’ appearance; c,
f EM micrographs of sarcomeres with good visual structure showing
well-deﬁned M-bands and Z-discs. Bar = 1 lm
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123Fig. 4 Electron micrographs of cardiac myectomy samples showing
low magniﬁcation (left) and high magniﬁcation (right) views. a (left)
Low magniﬁcation survey of MH1 showing an overview of myoﬁbr-
illar organisation. a (right) Micrograph of MH1 showing good, intact
sarcomere. b, c Electron micrographs for M4 and M9 respectively
conﬁrm the preservation of sarcomere structure in both samples.
Intact sarcomeres with straight M-bands and well-preserved Z-discs
can be identiﬁed for all three samples. Bar = 1 lm
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123In order to conﬁrm the positioning of these C-zone
peaks, the proﬁle plots from the DA-1 skeletal muscle with
MYBPC1 mutations were aligned and compared with the
axial density proﬁle plot derived from frog sartorius (fast)
skeletal muscle (Fig. 5). Figure 5a shows the proﬁle plot
for fast skeletal muscle from frog sartorius (reproduced
with permission from Luther et al. 2008). In fast skeletal
muscle, the C-zone spans over seven stripes, stripe 5–11,
while in slow skeletal muscle, the C-zone spans over nine
stripes, stripe 3–11 (Bennett et al. 1986). Since the mutant
samples were obtained from abductor hallucis muscle
which is composed of type I and type II ﬁbres, we spe-
ciﬁcally identiﬁed type I ﬁbres by measuring the Z-disc
width in the electron micrographs. Only sarcomeres in
which the Z-discs had widths of 100–140 nm were used in
our analysis (Luther 2009). The proﬁle plots for the two
mutant samples, ss-W236R and ss-Y856H, show well
preserved M-bands (Fig. 5b, c). For both the mutant sam-
ples, the presence of MyBP-C is evident from the several
43 nm peaks in the C-zone; however all nine peaks are not
equivalent. For sample ss-W236R (Fig. 5b), distinct peaks
are present which correlate with positions of the peaks
5–11 in the frog muscle in Fig. 5a, however the amplitude
of the peaks is quite variable. Sample ss-Y856H (Fig. 5c)
shows stripes at position 5–10 that correlate with the
position of the peaks in the frog muscle (Fig. 5a). The
irregularities observed in the peak amplitude for ss-W236R
could be due to sample preparation artefacts or it could
indicate a possible disruption in protein incorporation in
those stripes. Further study is required to resolve this.
Fig. 5 Averaged axial density proﬁle plots of skeletal muscle with
MYBPC1 mutations and control samples. The proﬁle plot from a frog
sartoriusmuscle is comparedwith the mean proﬁle plots ofb ss-W236R
and c ss-Y856H. The left panel shows an example electron micrograph
used to calculate the average proﬁle plots in the right panel. The proﬁle
plots are aligned at the centre of the M-band and the edge of the A-band
(green lines)a n d1 7red stripes of 43-nm spacing. a Reproduced from
Luther et al. (2008) with permission fromElsevier. (Color ﬁgure online)
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123Fig. 6 Averaged axial density
plot proﬁles of the cardiac
mutants and control samples.
The proﬁle plots are precisely
lined up as described
previously, along the centre of
the M-band and the edge of the
A-band. The 9 stripes due to
cMyBP-C are labelled as the
C-zone. a Proﬁle plot derived
from rat cardiac muscle
(papillary) cryosections was
compared with the average
proﬁle plot for the HCM
myectomy samples: b M24
myectomy control sample;
c MH1, d M4, e M9. Distinct
and regular peaks can be
observed in the C-zone of the
cardiac mutant samples that
coincide with the cMyBP-C
axial spacing of 43 nm (red
stripes). These plots were also
compared with f mouse cMyBP-
C-ko muscle cryosections.
MyBP-C stripes are
considerably suppressed in the
cMyBP-C-ko muscle. a,
f Reproduced from Luther et al.
(2008) with permission from
Elsevier. (Color ﬁgure online)
70 J Muscle Res Cell Motil (2012) 33:61–74
123The cardiac HCM samples (M24, MH1, M4 and M9) are
analysed in Fig 6. Their proﬁle plots were aligned with the
proﬁle plot derived from rat cardiac muscle (reproduced
with permission from Luther et al. 2008). Figure 6a shows
the proﬁle plot for the rat cardiac sections, the C-zone
spanning 9 stripes from stripe 3–11. The myectomy control
sample, M24 (Fig. 6b), shows excellent correlation spa-
tially and in amplitude with the rat cardiac proﬁle and
distinct peaks are evident in all the 9 positions. Like the rat
cardiac sample, this sample was prepared by cryosection-
ing as described in Luther et al. (2008); this technique
gives particularly high resolution structural detail e.g. it
shows the presence of the two layers of myosin crowns
between each pair of 43 nm stripe (the 43 nm stripes are a
summation of MyBP-C and one layer of myosin crowns).
Such detail is often less clear in plastic embedded sections.
The mutant samples (Fig. 6c, d, e) also show good spatial
correlation with the C-zone peaks but the resolution of
detail is variable. The plot for MH1 (Fig. 6c) is regular,
with C-zone peaks of similar amplitudes, but only 6 out of
the 9 peaks are well matched and the resolution between
the peaks is low in this plastic embedded sample. For M4
and M9 (Fig. 6d, e, respectively), the C-zone peaks are
clear with better crown detail; for M4 all the C-zone stripes
are well matched, except for stripes 4 and 11 which are
considerably suppressed. For sample M9 (Fig. 6e), all 9
C-zone stripes are distinct and comparable with Fig. 6a, b.
The axial density plots of the cardiac mutant samples, in
comparison with the control skeletal and cardiac models,
clearly show evidence of cMyBP-C expression and its
incorporation in the C-zone. The sharpness of the peaks
further indicates that cMyBP-C is conﬁned to a narrow disc
axially and is not altered in the diseased state.
Comparison with mouse cMyBP-C-ko model
We further compared the cardiac mutant samples with axial
density distribution of mouse cMyBP-C-ko muscle
(Fig. 6f; reproduced with permission from Luther et al.
2008). Luther et al. looked at the effects of cMyBP-C
deﬁciency on the axial density distribution in the C-zones
of the knockout mice. As shown in Fig. 6f, the C-zone
Fig. 7 1-D Fourier transforms of cardiac samples a Rat cardiac
muscle, b Myectomy control sample M24, c Cardiac HCM samples
MH1, d M9 and e cMyBP-C-ko muscle. The plots are aligned
precisely with red lines going through the 43, 21.5, 14.3 nm spots
(orders of 43 nm) and through the 38.5 nm spot corresponding to
troponin. The 43 and 21.5 nm spots are referred to as forbidden
meridionals, since they would not be observed if the thick ﬁlament
symmetry was strictly helical. In MyBP-C-ko cardiac muscle, the
21.5-nm reﬂection is completely absent and the 43-nm peak is greatly
diminished, but they are evident for HCM cardiac samples and rat
cardiac muscle. a, e Reproduced from Luther et al. (2008) with
permission from Elsevier. (Color ﬁgure online)
b
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123peaks at each of the stripes 3–11 are considerably sup-
pressed (Luther et al. 2008). This is in contrast to the
distinct, regular peaks observed in the C-zone of the car-
diac mutant samples that coincide with the densities cor-
responding to MyBP-C stripe positions in the rat cardiac
and human myectomy control sample.
Fourier transform analysis of the proﬁle plots
One-dimensional Fourier transforms for rat cardiac muscle
(reproduced with permission from Luther et al. 2008),
cardiac HCM samples M24, MH1 and M9 are shown in
Fig. 7a–d, respectively, aligned with the Fourier transform
of the mouse cMyBP-C-ko muscle cryosection in Fig. 7e
(reproduced with permission from Luther et al. 2008). In
the transforms for the HCM samples in Fig. 7b–d, the
reﬂections corresponding to the forbidden meridionals at
43 and 21.5 nm are prominent, and align well with the
transform for rat cardiac muscle (Fig. 7a). In contrast, the
1-D transform of the cMyBP-C-ko muscle (Fig. 7e) shows
completely absent 21.5-nm reﬂection and a greatly
diminished 43 nm peak. The reﬂections at 14.3 nm due to
the myosin crossbridge repeat are clearly present in all the
samples (except for M9). This is a normal reﬂection on the
meridian unlike the meridional 43 and 21.5 nm spots which
are ‘‘forbidden’’ spots. Hence the mouse knockout lacking
cMyBP-C has very weak forbidden spots, compared to
human cardiac muscle with HCM-causing MYBPC3
mutations. This suggests that although mutant cMyBP-C is
not detected in human cardiac samples, the heterozygous
allele contributes sufﬁcient cMyBP-C protein to the C-zone
banding pattern for this type of structural analysis.
Discussion
Development of cardiomyopathy and skeletal muscle
myopathy due to missing or aberrant MyBP-C protein
highlights the importance of studying MyBP-C and
understanding its role in the sarcomere. HCM causing
MYBPC3 mutations (both missense and nonsense muta-
tions) are numerous and well documented (Harris et al.
2011). About two-thirds of MYBPC3 mutations are pre-
dicted to generate truncated protein products that have so
far not been detected in myocardial samples. Missense
mutations resulting in single amino acid substitutions have
been identiﬁed to occur throughout the protein sequence.
Cardiac MyBP-C with the E542Q missense mutation (MH1
in this study) showed evidence of sarcomeric incorporation
comparable to endogenous cMyBP-C when expressed in
rat fetal cardiomyocytes (Flavigny et al. 1999). However
there is still no direct experimental evidence from patient
biopsy samples supporting a poison peptide mechanism for
missense MYBPC3 mutations. In fact levels of cMyBP-C
measured from myectomy samples appear to be reduced in
HCM samples compared to the controls, supporting hap-
loinsufﬁciency as the disease-causing mechanism (Marston
et al. 2009, 2011; Van Dijk et al. 2009).
To date only two slow skeletal muscle MYBPC1 muta-
tions have been identiﬁed; these are missense mutations
and both occur in highly conserved regions. The W236R
mutation occurs in the MyBP-C motif, while the Y856H
mutation is located in a partially exposed region of the C8
domain (Gurnett et al. 2010). Unlike cMyBP-C in HCM
patients, the level of total ssMyBP-C was not found to
differ between patients with the W236R and Y856H MY-
BPC1 mutations and controls. Also preliminary studies
carried out using GFP-tagged ssMyBPC showed normal
localisation of wild type ssMyBP-C as well as mutant ss-
W236R and ss-Y856H in mouse epitrochlearis muscle; in
contrast there was poor localisation of MyBP-C containing
homologous cardiac mutations (Gurnett et al. 2010).
The results discussed here provide useful insights into
the structural consequence of MyBP-C gene mutation. The
following observations emerge for both the cardiac and
skeletal muscle speciﬁc mutation:
(1) The ultrastructure of the sarcomere in longitudinal
sections appears to be well preserved despite the
phenotype of muscle disorder.
(2) Image analysis conﬁrms MyBP-C incorporation into
the A-band and sharpness of peaks further indicates
that it is conﬁned to a narrow disc axially.
(3) Comparison with the cardiac MyBP-C ko model
provides no indication of altered axial distribution in
the HCM samples.
The axial distribution that we observe is due to projec-
tion of density through the depth of the section. If all
MyBP-C molecules lie in the same plane in longitudinal
view, it would give rise to sharp peaks in averaged plot
proﬁles. If there is movement in MyBP-C N-terminal
‘‘arms’’ within the same plane this would not affect the
axial density and the stripes would remain sharp. Similarly,
if a few N-terminus domains move out of the plane, this
would reduce the density of the peaks but only by a little
and still show clear peaks by our averaging method. A
stripe would not be visualised only if the MyBP-C arms
move out of the plane at the C-terminus of the protein. Our
results suggest that MyBP-C remains conﬁned to a disc and
structurally intact at the C-terminus. But the state of
N-terminus cannot be commented upon from these results
and electron tomography of transverse sections of the
muscle is required to investigate the disposition of N-ter-
minal half of MyBP-C.
The 1-D Fourier transforms of the cardiac proﬁle plots
and comparison with cardiac MyBP-C ko model further
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123conﬁrms the notion that cMyBP-C is incorporated and
axially distributed correctly. X-ray diffraction patterns of
striated muscle show forbidden meridional reﬂections
corresponding to the ﬁrst, second, fourth, etc. orders of
42.9 nm; the presence of which may be caused by varia-
tions in the myosin head spacing or the presence of
accessory proteins such as MyBP-C at every third myosin
head repeat or a combination of both. For the cardiac HCM
samples both the 21.5 and 43 nm peaks occur prominently,
which are signiﬁcantly suppressed in the cMyBP-C ko
muscle. Thus the forbidden meridionals appear to be
unaffected in these HCM causing cardiac mutations, sug-
gesting the thick ﬁlament arrangement is not disrupted.
However, these data do not explain the apparent
reduction (*20 %) in the amount of cMyBP-C in HCM
patients with MYBPC3 mutations (Marston et al. 2009).
With the heterozygous allele contributing a high level of
wild type cMyBP-C, such a reduction (*20 %) may not be
resolved by the methods used in this study. The samples
used for electron microscopy with the current methods
have a lot of variability and the absolute levels of density
are hard to determine unambiguously. In addition, artefacts
from the muscle preparation techniques increase the noise
in the density proﬁles. Samples prepared by cryosectioning
(Luther et al. 2008) or fast freezing and freeze substitution
(Luther et al. 2011) have superior preservation and can
even show the 14.3 sub-bands arising due to the crown
densities in each 43 nm period. However this is difﬁcult to
achieve for human biopsy/myectomy samples. Plastic
sections prepared by conventional processing methods
show good morphology but ﬁne details like the 14.3 nm
sub-bands are harder to preserve. Hence in this study the
banding pattern reliably demonstrates the location of pro-
teins rather than their relative abundance. To assess the
amount of protein from the density in the electron micro-
scope, more specialised methods are required like mass
measurement by scanning transmission electron micros-
copy (e.g. Liversage et al. 2001).
In summary, we describe here the ﬁrst EM based anal-
ysis of human cardiac and skeletal muscle samples with
MyBP-C gene mutations. From our current method of
analysis, incorporation and axial density distribution of the
protein appears to be unaffected, as is evident from the
axial density plot and the 1-D Fourier transform.
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